融券方面，凯普生物1月6日融券偿还600.00股，融券卖出1400.00股，按当日收盘价计算，卖出金额 7910.00元；融券余量7400.00股，融券余额4.18万元，低于近一年50%分位水平，处于较低位。 资料显示，广东凯普生物科技股份有限公司位于广东省潮州市经济开发试验区北片高新区D5-3-3-4小 区，成立日期2003年6月13日，上市日期2017年4月12日，公司主营业务涉及分子诊断试剂、分子诊断配 套仪器等体外诊断相关产品的研发、生产和销售,并提供相关服务。主营业务收入构成为：自产产品 67.58%，检验服务30.89%，其他(补充)1.53%。 1月6日，凯普生物跌0.35%，成交额4951.86万元。两融数据显示，当日凯普生物获融资买入额253.78万 元，融资偿还686.50万元，融资净买入-432.72万元。截至1月6日，凯普生物融资融券余额合计8874.98 万元。 分红方面，凯普生物A股上市后累计派现4.85亿元。近三年，累计派现1.93亿元。 融资方面，凯普生物当日融资买入253.78万元。当前融资余额8870.80万元，占流通市值的2.43%，融资 余额低于近一年10%分位水平，处 ...

Core Viewpoint - 凯普生物 is a leading provider of molecular diagnostic products and services in China, with a focus on the full industry chain of nucleic acid testing [1] Group 1: Business Overview - Established on June 13, 2003, and listed on the Shenzhen Stock Exchange on April 12, 2017, 凯普生物 is headquartered in Chaozhou, Guangdong Province [1] - The company's main business includes the research, production, and sales of molecular diagnostic reagents and related instruments, as well as providing relevant services [1] - The company operates within the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics, with concepts including private hospitals and gene sequencing [1] Group 2: Financial Performance - For Q3 2025, 凯普生物 reported revenue of 486 million yuan, ranking 18th out of 39 in the industry, below the industry average of 708 million yuan [2] - The company experienced a net loss of 189 million yuan during the same period, ranking 37th out of 39, while the industry average net profit was 110 million yuan [2] - The top performer in the industry, 新产业, achieved revenue of 3.428 billion yuan, with a median revenue of 330 million yuan [2] Group 3: Financial Ratios - As of Q3 2025, 凯普生物's debt-to-asset ratio was 12.93%, an increase from 10.04% year-on-year, but still below the industry average of 18.29% [3] - The gross profit margin for Q3 2025 was 47.56%, down from 53.81% year-on-year, and also below the industry average of 56.20% [3] Group 4: Executive Compensation - The chairman, 管乔中, received a salary of 2.0459 million yuan in 2024, a decrease of 120,800 yuan from 2023 [4] - The general manager, 王建瑜, earned 1.9316 million yuan in 2024, down by 97,100 yuan from the previous year [4] Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 0.10% to 28,200 [5] - The average number of circulating A-shares held per shareholder decreased by 0.10% to 22,500 [5] - Among the top ten circulating shareholders, the medical device ETF (159883) is the ninth largest, holding 2.392 million shares as a new shareholder [5]

Group 1 - The core viewpoint of the news is that Capbio has experienced fluctuations in its stock price and financial performance, with a recent increase in stock price but a decline in revenue and profit for the first half of 2025 [1][2]. Group 2 - As of October 21, Capbio's stock price rose by 2.15% to 5.71 CNY per share, with a total market capitalization of 3.692 billion CNY [1]. - Year-to-date, Capbio's stock price has decreased by 3.71%, with a 2.33% increase over the last five trading days, but a decline of 3.38% over the last 20 days and 10.78% over the last 60 days [1]. - The company reported a revenue of 315 million CNY for the first half of 2025, a year-on-year decrease of 22.96%, and a net profit of -89.59 million CNY, a year-on-year decrease of 16.46% [2]. - Capbio's main business revenue composition includes 67.58% from self-produced products, 30.89% from inspection services, and 1.53% from other sources [1]. - The company has distributed a total of 485 million CNY in dividends since its A-share listing, with 193 million CNY distributed in the last three years [3].